nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoteridol—Gingivitis—Epirubicin—ovarian cancer	0.0054	0.0054	CcSEcCtD
Gadoteridol—Ill-defined disorder—Topotecan—ovarian cancer	0.00523	0.00523	CcSEcCtD
Gadoteridol—Injection site pain—Epirubicin—ovarian cancer	0.00519	0.00519	CcSEcCtD
Gadoteridol—Flushing—Vinorelbine—ovarian cancer	0.00514	0.00514	CcSEcCtD
Gadoteridol—Cardiac arrest—Paclitaxel—ovarian cancer	0.00512	0.00512	CcSEcCtD
Gadoteridol—Malaise—Topotecan—ovarian cancer	0.00508	0.00508	CcSEcCtD
Gadoteridol—Gingivitis—Doxorubicin—ovarian cancer	0.005	0.005	CcSEcCtD
Gadoteridol—Cough—Topotecan—ovarian cancer	0.00492	0.00492	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Epirubicin—ovarian cancer	0.00483	0.00483	CcSEcCtD
Gadoteridol—Erythema—Vinorelbine—ovarian cancer	0.00482	0.00482	CcSEcCtD
Gadoteridol—Cough—Melphalan—ovarian cancer	0.00482	0.00482	CcSEcCtD
Gadoteridol—Injection site pain—Doxorubicin—ovarian cancer	0.00481	0.00481	CcSEcCtD
Gadoteridol—Chest pain—Topotecan—ovarian cancer	0.0048	0.0048	CcSEcCtD
Gadoteridol—Convulsion—Melphalan—ovarian cancer	0.00478	0.00478	CcSEcCtD
Gadoteridol—Discomfort—Topotecan—ovarian cancer	0.00474	0.00474	CcSEcCtD
Gadoteridol—Chest pain—Melphalan—ovarian cancer	0.0047	0.0047	CcSEcCtD
Gadoteridol—Dysphagia—Paclitaxel—ovarian cancer	0.00465	0.00465	CcSEcCtD
Gadoteridol—Lacrimation increased—Epirubicin—ovarian cancer	0.0046	0.0046	CcSEcCtD
Gadoteridol—Anaphylactic shock—Topotecan—ovarian cancer	0.0046	0.0046	CcSEcCtD
Gadoteridol—Anaphylactic shock—Melphalan—ovarian cancer	0.0045	0.0045	CcSEcCtD
Gadoteridol—Oedema—Melphalan—ovarian cancer	0.0045	0.0045	CcSEcCtD
Gadoteridol—Ill-defined disorder—Vinorelbine—ovarian cancer	0.00447	0.00447	CcSEcCtD
Gadoteridol—Cardiovascular disorder—Doxorubicin—ovarian cancer	0.00447	0.00447	CcSEcCtD
Gadoteridol—Hyperhidrosis—Topotecan—ovarian cancer	0.00445	0.00445	CcSEcCtD
Gadoteridol—Pain—Chlorambucil—ovarian cancer	0.00442	0.00442	CcSEcCtD
Gadoteridol—Malaise—Vinorelbine—ovarian cancer	0.00435	0.00435	CcSEcCtD
Gadoteridol—Lacrimation increased—Doxorubicin—ovarian cancer	0.00426	0.00426	CcSEcCtD
Gadoteridol—Feeling abnormal—Chlorambucil—ovarian cancer	0.00426	0.00426	CcSEcCtD
Gadoteridol—Injection site reaction—Epirubicin—ovarian cancer	0.00422	0.00422	CcSEcCtD
Gadoteridol—Hypotension—Melphalan—ovarian cancer	0.00421	0.00421	CcSEcCtD
Gadoteridol—Cough—Vinorelbine—ovarian cancer	0.00421	0.00421	CcSEcCtD
Gadoteridol—Hypertension—Vinorelbine—ovarian cancer	0.00416	0.00416	CcSEcCtD
Gadoteridol—Paraesthesia—Topotecan—ovarian cancer	0.00413	0.00413	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Epirubicin—ovarian cancer	0.00412	0.00412	CcSEcCtD
Gadoteridol—Urticaria—Chlorambucil—ovarian cancer	0.0041	0.0041	CcSEcCtD
Gadoteridol—Chest pain—Vinorelbine—ovarian cancer	0.0041	0.0041	CcSEcCtD
Gadoteridol—Dyspnoea—Topotecan—ovarian cancer	0.0041	0.0041	CcSEcCtD
Gadoteridol—Abdominal pain—Chlorambucil—ovarian cancer	0.00408	0.00408	CcSEcCtD
Gadoteridol—Body temperature increased—Chlorambucil—ovarian cancer	0.00408	0.00408	CcSEcCtD
Gadoteridol—Discomfort—Vinorelbine—ovarian cancer	0.00406	0.00406	CcSEcCtD
Gadoteridol—Paraesthesia—Melphalan—ovarian cancer	0.00404	0.00404	CcSEcCtD
Gadoteridol—Fluid retention—Epirubicin—ovarian cancer	0.00403	0.00403	CcSEcCtD
Gadoteridol—Dyspnoea—Melphalan—ovarian cancer	0.00402	0.00402	CcSEcCtD
Gadoteridol—Dysphagia—Docetaxel—ovarian cancer	0.00394	0.00394	CcSEcCtD
Gadoteridol—Anaphylactic shock—Vinorelbine—ovarian cancer	0.00393	0.00393	CcSEcCtD
Gadoteridol—Pain—Topotecan—ovarian cancer	0.00393	0.00393	CcSEcCtD
Gadoteridol—Injection site reaction—Doxorubicin—ovarian cancer	0.0039	0.0039	CcSEcCtD
Gadoteridol—Rash maculo-papular—Epirubicin—ovarian cancer	0.00385	0.00385	CcSEcCtD
Gadoteridol—Pain—Melphalan—ovarian cancer	0.00385	0.00385	CcSEcCtD
Gadoteridol—Salivary hypersecretion—Doxorubicin—ovarian cancer	0.00381	0.00381	CcSEcCtD
Gadoteridol—Hypersensitivity—Chlorambucil—ovarian cancer	0.00381	0.00381	CcSEcCtD
Gadoteridol—Bradycardia—Paclitaxel—ovarian cancer	0.00379	0.00379	CcSEcCtD
Gadoteridol—Feeling abnormal—Topotecan—ovarian cancer	0.00379	0.00379	CcSEcCtD
Gadoteridol—Rhinitis—Paclitaxel—ovarian cancer	0.00373	0.00373	CcSEcCtD
Gadoteridol—Fluid retention—Doxorubicin—ovarian cancer	0.00373	0.00373	CcSEcCtD
Gadoteridol—Hypotension—Vinorelbine—ovarian cancer	0.00368	0.00368	CcSEcCtD
Gadoteridol—Pruritus—Chlorambucil—ovarian cancer	0.00366	0.00366	CcSEcCtD
Gadoteridol—Urticaria—Topotecan—ovarian cancer	0.00365	0.00365	CcSEcCtD
Gadoteridol—Body temperature increased—Topotecan—ovarian cancer	0.00364	0.00364	CcSEcCtD
Gadoteridol—Abdominal pain—Topotecan—ovarian cancer	0.00364	0.00364	CcSEcCtD
Gadoteridol—Urticaria—Melphalan—ovarian cancer	0.00358	0.00358	CcSEcCtD
Gadoteridol—Rash maculo-papular—Doxorubicin—ovarian cancer	0.00357	0.00357	CcSEcCtD
Gadoteridol—Diarrhoea—Chlorambucil—ovarian cancer	0.00354	0.00354	CcSEcCtD
Gadoteridol—Paraesthesia—Vinorelbine—ovarian cancer	0.00353	0.00353	CcSEcCtD
Gadoteridol—Dyspnoea—Vinorelbine—ovarian cancer	0.00351	0.00351	CcSEcCtD
Gadoteridol—Tinnitus—Paclitaxel—ovarian cancer	0.00347	0.00347	CcSEcCtD
Gadoteridol—Flushing—Paclitaxel—ovarian cancer	0.00346	0.00346	CcSEcCtD
Gadoteridol—Hypersensitivity—Topotecan—ovarian cancer	0.00339	0.00339	CcSEcCtD
Gadoteridol—Pain—Vinorelbine—ovarian cancer	0.00336	0.00336	CcSEcCtD
Gadoteridol—Hypersensitivity—Melphalan—ovarian cancer	0.00332	0.00332	CcSEcCtD
Gadoteridol—Vomiting—Chlorambucil—ovarian cancer	0.00329	0.00329	CcSEcCtD
Gadoteridol—Pruritus—Topotecan—ovarian cancer	0.00325	0.00325	CcSEcCtD
Gadoteridol—Erythema—Paclitaxel—ovarian cancer	0.00324	0.00324	CcSEcCtD
Gadoteridol—Feeling abnormal—Vinorelbine—ovarian cancer	0.00324	0.00324	CcSEcCtD
Gadoteridol—Pruritus—Melphalan—ovarian cancer	0.00319	0.00319	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Epirubicin—ovarian cancer	0.00318	0.00318	CcSEcCtD
Gadoteridol—Dysgeusia—Paclitaxel—ovarian cancer	0.00318	0.00318	CcSEcCtD
Gadoteridol—Rhinitis—Docetaxel—ovarian cancer	0.00317	0.00317	CcSEcCtD
Gadoteridol—Diarrhoea—Topotecan—ovarian cancer	0.00315	0.00315	CcSEcCtD
Gadoteridol—Urticaria—Vinorelbine—ovarian cancer	0.00313	0.00313	CcSEcCtD
Gadoteridol—Abdominal pain—Vinorelbine—ovarian cancer	0.00311	0.00311	CcSEcCtD
Gadoteridol—Body temperature increased—Vinorelbine—ovarian cancer	0.00311	0.00311	CcSEcCtD
Gadoteridol—Diarrhoea—Melphalan—ovarian cancer	0.00308	0.00308	CcSEcCtD
Gadoteridol—Nausea—Chlorambucil—ovarian cancer	0.00307	0.00307	CcSEcCtD
Gadoteridol—Dizziness—Topotecan—ovarian cancer	0.00304	0.00304	CcSEcCtD
Gadoteridol—Tremor—Paclitaxel—ovarian cancer	0.00304	0.00304	CcSEcCtD
Gadoteridol—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00301	0.00301	CcSEcCtD
Gadoteridol—Face oedema—Epirubicin—ovarian cancer	0.00297	0.00297	CcSEcCtD
Gadoteridol—Anaphylactoid reaction—Doxorubicin—ovarian cancer	0.00294	0.00294	CcSEcCtD
Gadoteridol—Flushing—Docetaxel—ovarian cancer	0.00293	0.00293	CcSEcCtD
Gadoteridol—Cardiac arrest—Epirubicin—ovarian cancer	0.00293	0.00293	CcSEcCtD
Gadoteridol—Vomiting—Topotecan—ovarian cancer	0.00292	0.00292	CcSEcCtD
Gadoteridol—Malaise—Paclitaxel—ovarian cancer	0.00292	0.00292	CcSEcCtD
Gadoteridol—Syncope—Paclitaxel—ovarian cancer	0.00291	0.00291	CcSEcCtD
Gadoteridol—Rash—Topotecan—ovarian cancer	0.0029	0.0029	CcSEcCtD
Gadoteridol—Hypersensitivity—Vinorelbine—ovarian cancer	0.0029	0.0029	CcSEcCtD
Gadoteridol—Dermatitis—Topotecan—ovarian cancer	0.0029	0.0029	CcSEcCtD
Gadoteridol—Headache—Topotecan—ovarian cancer	0.00288	0.00288	CcSEcCtD
Gadoteridol—Vomiting—Melphalan—ovarian cancer	0.00286	0.00286	CcSEcCtD
Gadoteridol—Loss of consciousness—Paclitaxel—ovarian cancer	0.00285	0.00285	CcSEcCtD
Gadoteridol—Rash—Melphalan—ovarian cancer	0.00284	0.00284	CcSEcCtD
Gadoteridol—Dermatitis—Melphalan—ovarian cancer	0.00284	0.00284	CcSEcCtD
Gadoteridol—Cough—Paclitaxel—ovarian cancer	0.00283	0.00283	CcSEcCtD
Gadoteridol—Convulsion—Paclitaxel—ovarian cancer	0.00281	0.00281	CcSEcCtD
Gadoteridol—Hypertension—Paclitaxel—ovarian cancer	0.0028	0.0028	CcSEcCtD
Gadoteridol—Pruritus—Vinorelbine—ovarian cancer	0.00278	0.00278	CcSEcCtD
Gadoteridol—Chest pain—Paclitaxel—ovarian cancer	0.00276	0.00276	CcSEcCtD
Gadoteridol—Anxiety—Paclitaxel—ovarian cancer	0.00275	0.00275	CcSEcCtD
Gadoteridol—Face oedema—Doxorubicin—ovarian cancer	0.00275	0.00275	CcSEcCtD
Gadoteridol—Erythema—Docetaxel—ovarian cancer	0.00275	0.00275	CcSEcCtD
Gadoteridol—Nausea—Topotecan—ovarian cancer	0.00273	0.00273	CcSEcCtD
Gadoteridol—Discomfort—Paclitaxel—ovarian cancer	0.00273	0.00273	CcSEcCtD
Gadoteridol—Cardiac arrest—Doxorubicin—ovarian cancer	0.00271	0.00271	CcSEcCtD
Gadoteridol—Dry mouth—Paclitaxel—ovarian cancer	0.0027	0.0027	CcSEcCtD
Gadoteridol—Diarrhoea—Vinorelbine—ovarian cancer	0.00269	0.00269	CcSEcCtD
Gadoteridol—Dysgeusia—Docetaxel—ovarian cancer	0.00269	0.00269	CcSEcCtD
Gadoteridol—Nausea—Melphalan—ovarian cancer	0.00268	0.00268	CcSEcCtD
Gadoteridol—Dysphagia—Epirubicin—ovarian cancer	0.00266	0.00266	CcSEcCtD
Gadoteridol—Oedema—Paclitaxel—ovarian cancer	0.00265	0.00265	CcSEcCtD
Gadoteridol—Anaphylactic shock—Paclitaxel—ovarian cancer	0.00265	0.00265	CcSEcCtD
Gadoteridol—Shock—Paclitaxel—ovarian cancer	0.0026	0.0026	CcSEcCtD
Gadoteridol—Dizziness—Vinorelbine—ovarian cancer	0.0026	0.0026	CcSEcCtD
Gadoteridol—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00256	0.00256	CcSEcCtD
Gadoteridol—Vomiting—Vinorelbine—ovarian cancer	0.0025	0.0025	CcSEcCtD
Gadoteridol—Rash—Vinorelbine—ovarian cancer	0.00248	0.00248	CcSEcCtD
Gadoteridol—Dermatitis—Vinorelbine—ovarian cancer	0.00248	0.00248	CcSEcCtD
Gadoteridol—Hypotension—Paclitaxel—ovarian cancer	0.00247	0.00247	CcSEcCtD
Gadoteridol—Headache—Vinorelbine—ovarian cancer	0.00247	0.00247	CcSEcCtD
Gadoteridol—Syncope—Docetaxel—ovarian cancer	0.00247	0.00247	CcSEcCtD
Gadoteridol—Dysphagia—Doxorubicin—ovarian cancer	0.00246	0.00246	CcSEcCtD
Gadoteridol—Loss of consciousness—Docetaxel—ovarian cancer	0.00242	0.00242	CcSEcCtD
Gadoteridol—Cough—Docetaxel—ovarian cancer	0.0024	0.0024	CcSEcCtD
Gadoteridol—Convulsion—Docetaxel—ovarian cancer	0.00238	0.00238	CcSEcCtD
Gadoteridol—Paraesthesia—Paclitaxel—ovarian cancer	0.00238	0.00238	CcSEcCtD
Gadoteridol—Hypertension—Docetaxel—ovarian cancer	0.00237	0.00237	CcSEcCtD
Gadoteridol—Dyspnoea—Paclitaxel—ovarian cancer	0.00236	0.00236	CcSEcCtD
Gadoteridol—Chest pain—Docetaxel—ovarian cancer	0.00234	0.00234	CcSEcCtD
Gadoteridol—Nausea—Vinorelbine—ovarian cancer	0.00234	0.00234	CcSEcCtD
Gadoteridol—Dry mouth—Docetaxel—ovarian cancer	0.00229	0.00229	CcSEcCtD
Gadoteridol—Sweating—Epirubicin—ovarian cancer	0.00227	0.00227	CcSEcCtD
Gadoteridol—Pain—Paclitaxel—ovarian cancer	0.00226	0.00226	CcSEcCtD
Gadoteridol—Oedema—Docetaxel—ovarian cancer	0.00224	0.00224	CcSEcCtD
Gadoteridol—Anaphylactic shock—Docetaxel—ovarian cancer	0.00224	0.00224	CcSEcCtD
Gadoteridol—Shock—Docetaxel—ovarian cancer	0.00221	0.00221	CcSEcCtD
Gadoteridol—Feeling abnormal—Paclitaxel—ovarian cancer	0.00218	0.00218	CcSEcCtD
Gadoteridol—Bradycardia—Epirubicin—ovarian cancer	0.00217	0.00217	CcSEcCtD
Gadoteridol—Rhinitis—Epirubicin—ovarian cancer	0.00214	0.00214	CcSEcCtD
Gadoteridol—Sweating—Doxorubicin—ovarian cancer	0.0021	0.0021	CcSEcCtD
Gadoteridol—Urticaria—Paclitaxel—ovarian cancer	0.0021	0.0021	CcSEcCtD
Gadoteridol—Hypotension—Docetaxel—ovarian cancer	0.0021	0.0021	CcSEcCtD
Gadoteridol—Body temperature increased—Paclitaxel—ovarian cancer	0.00209	0.00209	CcSEcCtD
Gadoteridol—Abdominal pain—Paclitaxel—ovarian cancer	0.00209	0.00209	CcSEcCtD
Gadoteridol—Paraesthesia—Docetaxel—ovarian cancer	0.00201	0.00201	CcSEcCtD
Gadoteridol—Bradycardia—Doxorubicin—ovarian cancer	0.00201	0.00201	CcSEcCtD
Gadoteridol—Dyspnoea—Docetaxel—ovarian cancer	0.002	0.002	CcSEcCtD
Gadoteridol—Tinnitus—Epirubicin—ovarian cancer	0.00199	0.00199	CcSEcCtD
Gadoteridol—Flushing—Epirubicin—ovarian cancer	0.00198	0.00198	CcSEcCtD
Gadoteridol—Rhinitis—Doxorubicin—ovarian cancer	0.00198	0.00198	CcSEcCtD
Gadoteridol—Hypersensitivity—Paclitaxel—ovarian cancer	0.00195	0.00195	CcSEcCtD
Gadoteridol—Pain—Docetaxel—ovarian cancer	0.00192	0.00192	CcSEcCtD
Gadoteridol—Pruritus—Paclitaxel—ovarian cancer	0.00187	0.00187	CcSEcCtD
Gadoteridol—Erythema—Epirubicin—ovarian cancer	0.00185	0.00185	CcSEcCtD
Gadoteridol—Feeling abnormal—Docetaxel—ovarian cancer	0.00185	0.00185	CcSEcCtD
Gadoteridol—Tinnitus—Doxorubicin—ovarian cancer	0.00184	0.00184	CcSEcCtD
Gadoteridol—Flushing—Doxorubicin—ovarian cancer	0.00183	0.00183	CcSEcCtD
Gadoteridol—Dysgeusia—Epirubicin—ovarian cancer	0.00182	0.00182	CcSEcCtD
Gadoteridol—Diarrhoea—Paclitaxel—ovarian cancer	0.00181	0.00181	CcSEcCtD
Gadoteridol—Body temperature increased—Docetaxel—ovarian cancer	0.00177	0.00177	CcSEcCtD
Gadoteridol—Abdominal pain—Docetaxel—ovarian cancer	0.00177	0.00177	CcSEcCtD
Gadoteridol—Dizziness—Paclitaxel—ovarian cancer	0.00175	0.00175	CcSEcCtD
Gadoteridol—Ill-defined disorder—Epirubicin—ovarian cancer	0.00172	0.00172	CcSEcCtD
Gadoteridol—Erythema—Doxorubicin—ovarian cancer	0.00172	0.00172	CcSEcCtD
Gadoteridol—Vomiting—Paclitaxel—ovarian cancer	0.00168	0.00168	CcSEcCtD
Gadoteridol—Dysgeusia—Doxorubicin—ovarian cancer	0.00168	0.00168	CcSEcCtD
Gadoteridol—Malaise—Epirubicin—ovarian cancer	0.00167	0.00167	CcSEcCtD
Gadoteridol—Rash—Paclitaxel—ovarian cancer	0.00167	0.00167	CcSEcCtD
Gadoteridol—Dermatitis—Paclitaxel—ovarian cancer	0.00167	0.00167	CcSEcCtD
Gadoteridol—Syncope—Epirubicin—ovarian cancer	0.00166	0.00166	CcSEcCtD
Gadoteridol—Headache—Paclitaxel—ovarian cancer	0.00166	0.00166	CcSEcCtD
Gadoteridol—Hypersensitivity—Docetaxel—ovarian cancer	0.00165	0.00165	CcSEcCtD
Gadoteridol—Loss of consciousness—Epirubicin—ovarian cancer	0.00163	0.00163	CcSEcCtD
Gadoteridol—Cough—Epirubicin—ovarian cancer	0.00162	0.00162	CcSEcCtD
Gadoteridol—Convulsion—Epirubicin—ovarian cancer	0.00161	0.00161	CcSEcCtD
Gadoteridol—Hypertension—Epirubicin—ovarian cancer	0.0016	0.0016	CcSEcCtD
Gadoteridol—Ill-defined disorder—Doxorubicin—ovarian cancer	0.00159	0.00159	CcSEcCtD
Gadoteridol—Pruritus—Docetaxel—ovarian cancer	0.00159	0.00159	CcSEcCtD
Gadoteridol—Chest pain—Epirubicin—ovarian cancer	0.00158	0.00158	CcSEcCtD
Gadoteridol—Anxiety—Epirubicin—ovarian cancer	0.00157	0.00157	CcSEcCtD
Gadoteridol—Nausea—Paclitaxel—ovarian cancer	0.00157	0.00157	CcSEcCtD
Gadoteridol—Discomfort—Epirubicin—ovarian cancer	0.00156	0.00156	CcSEcCtD
Gadoteridol—Malaise—Doxorubicin—ovarian cancer	0.00155	0.00155	CcSEcCtD
Gadoteridol—Dry mouth—Epirubicin—ovarian cancer	0.00154	0.00154	CcSEcCtD
Gadoteridol—Syncope—Doxorubicin—ovarian cancer	0.00154	0.00154	CcSEcCtD
Gadoteridol—Diarrhoea—Docetaxel—ovarian cancer	0.00153	0.00153	CcSEcCtD
Gadoteridol—Oedema—Epirubicin—ovarian cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Anaphylactic shock—Epirubicin—ovarian cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Loss of consciousness—Doxorubicin—ovarian cancer	0.00151	0.00151	CcSEcCtD
Gadoteridol—Cough—Doxorubicin—ovarian cancer	0.0015	0.0015	CcSEcCtD
Gadoteridol—Shock—Epirubicin—ovarian cancer	0.00149	0.00149	CcSEcCtD
Gadoteridol—Convulsion—Doxorubicin—ovarian cancer	0.00149	0.00149	CcSEcCtD
Gadoteridol—Dizziness—Docetaxel—ovarian cancer	0.00148	0.00148	CcSEcCtD
Gadoteridol—Hypertension—Doxorubicin—ovarian cancer	0.00148	0.00148	CcSEcCtD
Gadoteridol—Hyperhidrosis—Epirubicin—ovarian cancer	0.00146	0.00146	CcSEcCtD
Gadoteridol—Chest pain—Doxorubicin—ovarian cancer	0.00146	0.00146	CcSEcCtD
Gadoteridol—Anxiety—Doxorubicin—ovarian cancer	0.00146	0.00146	CcSEcCtD
Gadoteridol—Discomfort—Doxorubicin—ovarian cancer	0.00144	0.00144	CcSEcCtD
Gadoteridol—Dry mouth—Doxorubicin—ovarian cancer	0.00143	0.00143	CcSEcCtD
Gadoteridol—Vomiting—Docetaxel—ovarian cancer	0.00143	0.00143	CcSEcCtD
Gadoteridol—Rash—Docetaxel—ovarian cancer	0.00141	0.00141	CcSEcCtD
Gadoteridol—Hypotension—Epirubicin—ovarian cancer	0.00141	0.00141	CcSEcCtD
Gadoteridol—Dermatitis—Docetaxel—ovarian cancer	0.00141	0.00141	CcSEcCtD
Gadoteridol—Headache—Docetaxel—ovarian cancer	0.00141	0.00141	CcSEcCtD
Gadoteridol—Anaphylactic shock—Doxorubicin—ovarian cancer	0.0014	0.0014	CcSEcCtD
Gadoteridol—Oedema—Doxorubicin—ovarian cancer	0.0014	0.0014	CcSEcCtD
Gadoteridol—Shock—Doxorubicin—ovarian cancer	0.00138	0.00138	CcSEcCtD
Gadoteridol—Paraesthesia—Epirubicin—ovarian cancer	0.00136	0.00136	CcSEcCtD
Gadoteridol—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00135	0.00135	CcSEcCtD
Gadoteridol—Dyspnoea—Epirubicin—ovarian cancer	0.00135	0.00135	CcSEcCtD
Gadoteridol—Nausea—Docetaxel—ovarian cancer	0.00133	0.00133	CcSEcCtD
Gadoteridol—Hypotension—Doxorubicin—ovarian cancer	0.00131	0.00131	CcSEcCtD
Gadoteridol—Pain—Epirubicin—ovarian cancer	0.00129	0.00129	CcSEcCtD
Gadoteridol—Paraesthesia—Doxorubicin—ovarian cancer	0.00126	0.00126	CcSEcCtD
Gadoteridol—Dyspnoea—Doxorubicin—ovarian cancer	0.00125	0.00125	CcSEcCtD
Gadoteridol—Feeling abnormal—Epirubicin—ovarian cancer	0.00125	0.00125	CcSEcCtD
Gadoteridol—Urticaria—Epirubicin—ovarian cancer	0.0012	0.0012	CcSEcCtD
Gadoteridol—Pain—Doxorubicin—ovarian cancer	0.0012	0.0012	CcSEcCtD
Gadoteridol—Abdominal pain—Epirubicin—ovarian cancer	0.0012	0.0012	CcSEcCtD
Gadoteridol—Body temperature increased—Epirubicin—ovarian cancer	0.0012	0.0012	CcSEcCtD
Gadoteridol—Feeling abnormal—Doxorubicin—ovarian cancer	0.00115	0.00115	CcSEcCtD
Gadoteridol—Hypersensitivity—Epirubicin—ovarian cancer	0.00111	0.00111	CcSEcCtD
Gadoteridol—Urticaria—Doxorubicin—ovarian cancer	0.00111	0.00111	CcSEcCtD
Gadoteridol—Abdominal pain—Doxorubicin—ovarian cancer	0.00111	0.00111	CcSEcCtD
Gadoteridol—Body temperature increased—Doxorubicin—ovarian cancer	0.00111	0.00111	CcSEcCtD
Gadoteridol—Pruritus—Epirubicin—ovarian cancer	0.00107	0.00107	CcSEcCtD
Gadoteridol—Diarrhoea—Epirubicin—ovarian cancer	0.00104	0.00104	CcSEcCtD
Gadoteridol—Hypersensitivity—Doxorubicin—ovarian cancer	0.00103	0.00103	CcSEcCtD
Gadoteridol—Dizziness—Epirubicin—ovarian cancer	0.001	0.001	CcSEcCtD
Gadoteridol—Pruritus—Doxorubicin—ovarian cancer	0.000991	0.000991	CcSEcCtD
Gadoteridol—Vomiting—Epirubicin—ovarian cancer	0.000962	0.000962	CcSEcCtD
Gadoteridol—Diarrhoea—Doxorubicin—ovarian cancer	0.000958	0.000958	CcSEcCtD
Gadoteridol—Rash—Epirubicin—ovarian cancer	0.000954	0.000954	CcSEcCtD
Gadoteridol—Dermatitis—Epirubicin—ovarian cancer	0.000953	0.000953	CcSEcCtD
Gadoteridol—Headache—Epirubicin—ovarian cancer	0.000948	0.000948	CcSEcCtD
Gadoteridol—Dizziness—Doxorubicin—ovarian cancer	0.000926	0.000926	CcSEcCtD
Gadoteridol—Nausea—Epirubicin—ovarian cancer	0.000899	0.000899	CcSEcCtD
Gadoteridol—Vomiting—Doxorubicin—ovarian cancer	0.00089	0.00089	CcSEcCtD
Gadoteridol—Rash—Doxorubicin—ovarian cancer	0.000883	0.000883	CcSEcCtD
Gadoteridol—Dermatitis—Doxorubicin—ovarian cancer	0.000882	0.000882	CcSEcCtD
Gadoteridol—Headache—Doxorubicin—ovarian cancer	0.000877	0.000877	CcSEcCtD
Gadoteridol—Nausea—Doxorubicin—ovarian cancer	0.000832	0.000832	CcSEcCtD
